Scientists test 'Living Drug' virus to hunt down stubborn lymphoma
NCT ID NCT07398963
Summary
This early-stage study is testing a new treatment for B-cell lymphoma that has come back or not responded to other therapies. The treatment uses a modified virus designed to both attack cancer cells directly and instruct the patient's own immune system to target them. Researchers will give the virus to 48 patients, either by injection into a tumor or into a vein, to first check its safety and find the right dose.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY/RELAPSED B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.